The mechanism analysis of allicin in hepatocellular carcinoma based on network pharmacology and immune infiltration

doi:10.14088/j.cnki.issn0439-8114.2022.10.014

Abstract

Abstract: The mechanism of allicin on hepatocellular carcinoma was explored using network pharmacology and immune infiltration. The effective composition information of allicin was collected by TCMSP database, and PharmMapper database was used to screen the targets of allicin; the above data were imported into STRING11.0 database for PPI network analysis, and then the protein interaction network was visualized by Cytoscape3.7.1 software. Hepatocellular carcinoma related targets were collected through the GeneCards database, then the targets of allicin were compared with the disease-related-targets, and Venny2.1.0 tool was used to draw the Venn diagram. GEPIA database was used to analyze the expression differences and survival prognosis of potential targets, and then TIMER database was used to analyze the immune infiltration of tumor cells. Results showed that 194 potential targets of allicin were screened and 31 targets related to HCC were identified. After screening with P<0.05,4 signal pathways were obtained. The therapeutic effect of allicin on hepatocellular carcinoma reflects the characteristics of multi-target, multi-pathway and multi-component of traditional Chinese medicine. CCNA2, AURKA, MMP9, ESR1 and other targets may play an important role in the treatment process.

Key words: allicin, hepatocellular carcinoma, network pharmacology, immune infiltration

CLC Number:

R285

DONG Xue-jing, ZHU Hua, WANG Ying. The mechanism analysis of allicin in hepatocellular carcinoma based on network pharmacology and immune infiltration[J]. HUBEI AGRICULTURAL SCIENCES, 2022, 61(10): 83-89.

References

[1] PETRICK J L, MCGLYNN K A.The changing epidemiology of primary liver cancer[J]. Current epidemiology reports, 2019, 6(2): 104-111.
[2] KHEMLINA G,IKEDA S,KURZROCK R.The biology of hepatocellular carcinoma:Implications for genomic and immune therapies[J]. Molecular cancer, 2017, 16(1): 149.
[3] AMBADE A, MANDREKAR P.Oxidative stress and inflammation: Essential partners in alcoholic liver disease[J]. Hepatology international, 2012, 2012: 853175.
[4] WALLACE M C,PREEN D, JEFFREY G P, et al.The evolving epidemiology of hepatocellular carcinoma: A global perspective[J]. Expert review of gastroenterology & hepatology, 2015, 9(6): 765-779.
[5] BRAY F, FERLAY J, SOERJOMATARAM I, et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. A cancer journal for clinicians, 2018, 68(6): 394-424.
[6] VALERY P C, LAVERSANNE M, CLARK P J, et al.Projections of primary liver cancer to 2030 in 30 countries worldwide[J]. Hepatology, 2017, 67(2): 600-611.
[7] 尹春晖,霍诗然. 大蒜素抗癌作用及其机制研究进展[J]. 食品科学, 2009, 30(7): 270-272.
[8] 张建永,杨沙,陈宽,等. 基于网络药理学的理气活血滴丸治疗心血管疾病作用机制研究[J]. 中药材, 2019(5): 1139-1145.
[9] 刘志华,孙晓波. 网络药理学:中医药现代化的新机遇[J]. 药学学报, 2012, 47(6): 696-703.
[10] 任俊泽,张展,李柏. 基于网络药理学探讨白头翁汤的抗肿瘤作用机制[J]. 世界临床药物, 2019, 40(4): 241-248.
[11] RAPPAPORT N, FISHILEVICH S, NUDEL R, et al.Rational confederation of genes and diseases: NGS interpretation via GeneCards, MalaCards and VarElect[J]. Biomedical engineering online, 2017, 16(1): 72.
[12] TANG Z, LI C, KANG B, et al.GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses[J]. Nucleic acids research, 2017, 45(1): 98-102.
[13] LI T, FAN J, WANG B, et al.TIMER: A web server for comprehensive analysis of tumor-infiltrating immune cells[J]. Cancer research, 2017, 77(21): 108-110.
[14] PAN J H, ZHOU H, COOPER L, et al.LAYN is a prognostic biomarker and correlated with immune infiltrates in gastric and colon cancers[J]. Frontiers in immunology, 2019, 10: 6.
[15] 薛潇春,胡晋红. 网络药理学的研究方法与应用进展[J]. 药学实践杂志, 2015, 33(5): 401-405.
[16] BAGNARDI V, ROTA M, BOTTERI E, et al.Alcohol consumption and site-specific cancer risk: A comprehensive dose-response meta-analysis[J]. British journal of cancer,2015,112(3):580-93.
[17] MCGLYNN K A, LONDON W T.The global epidemiology of hepatocellular carcinoma: Present and future[J]. Clinics in liver disease, 2011, 15(2): 223-243.
[18] ALZAHRANI B, ISELI T J, HEBBARD L W.Non-viral causes of liver cancer: Does obesity led inflammation play a role[J]. Cancer letters, 2014, 345(2): 223-229.
[19] LIU Y, CHANG C H, MARSH G M, et al.Population attributable risk of aflatoxin-related liver cancer: Systematic review and meta-analysis[J]. European journal of cancer, 2012, 48(14): 2125-2136.
[20] NELSON N P, EASTERBROOK P J, MCMAHON B J.Epidemiology of Hepatitis B virus infection and impact of vaccination on disease[J]. Clinics in liver disease, 2016, 20(4): 607-628.
[21] 刘丹璐,邓云丹,崔芬芬,等. 大蒜素对肝癌细胞血道转移的影响[J]. 亚太传统医药, 2012, 8(9): 47-48.
[22] THOMAS N E, BUSAM K J, FROM L, et al.Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study[J]. Journal of clinical oncology, 2013, 31(33): 4252-4259.
[23] GAO T, HAN Y, YU L, et al.CCNA2 is a prognostic biomarker for ER+ breast cancer and tamoxifen resistance[J]. PLoS One, 2014, 9(3): e91771.
[24] KIM D H, PARK S E, KIM M, et al.A functional single nucleotide polymorphism at the promoter region of cyclin A2 is associated with increased risk of colon, liver, and lung cancers[J]. Cancer, 2011, 117(17): 4080-4091.
[25] SAKAMOTO Y, MAFUNE K, MORI M, et al.Overexpression of MMP-9 correlates with growth of small hepatocellular carcinoma[J]. International journal of oncology, 2000, 17(2): 237-280.
[26] ICHIRO S,SUSUMU I.Protection of estrogens against the progression of chronic liver disease[J]. Hepatology research,2007,37(4):239-247.
[27] OKASHA S A,YU S, DO Y, et al.Evidence for estradiol-induced apoptosis and dysregulated T cell maturation in the thymus[J]. Toxicology, 2001, 163(1): 49-62.
[28] ODOM D T,ZIZLSPERGER N,GORDON D B,et al.Control of pancreas and liver gene expression by HNF transcription factors[J]. Science, 2004, 303(5662): 1378-1381.
[29] WANG S H, YEH S H, LIN W H, et al.Estrogen receptor α represses transcription of HBV genes via interaction with hepatocyte nuclear factor 4α[J]. Gastroenterology, 2012, 142(4): 989-998.